BioMarin agreed to acquire Amicus Therapeutics in an all‑cash transaction valued at about $4.8 billion, adding two marketed therapies for Pompe and Fabry diseases and U.S. rights to a late‑stage candidate for focal segmental glomerulosclerosis. Boards of both companies approved the deal, which is expected to close in Q2 2026. BioMarin said the purchase brings immediate commercial revenue and a late‑stage asset (DMX‑200) that diversifies its rare disease pipeline. CEO Alexander Hardy framed the transaction as a move to accelerate a series of strategic deals to rebuild BioMarin’s commercial momentum and offset prior gene‑therapy setbacks. Analysts noted the acquisition supplies BioMarin with approved products and manufacturing or clinical assets that can generate near‑term cash flow while the company retools its pipeline. The deal also underscores larger sector activity: rare‑disease consolidation remains an attractive route for mid‑cap biotechs seeking scale and recurring revenue.